Physician profile
Kai Wu
NPI 1114186079
$3,975.67
in general payments reported to CMS, 2019-2025
29 companies · $521 in 2025
The $521 reported for 2025 was more than what 81% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $488 · 2020: $354 · 2021: $896 · 2022: $662 · 2023: $461 · 2024: $593 · 2025: $521.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,535 · Education: $40.05.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,535.44 |
| Education | $40.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $937.03 | 2019-2025 | Lo Loestrin Fe, Orilissa, Liletta |
| Amgen INC. | $330.49 | 2019-2022 | |
| Astellas Pharma US INC | $295.56 | 2020-2025 | Veozah |
| Caldera Medical, INC | $230.26 | 2023-2024 | Desara |
| Myovant Sciences INC. | $191.11 | 2021-2022 | |
| Shield Therapeutics INC | $189.35 | 2023-2025 | Accrufer |
| Daiichi Sankyo INC. | $177.50 | 2021-2022 | |
| Mayne Pharma Commercial LLC | $170.66 | 2021-2025 | |
| Sage Therapeutics, LLC | $153.56 | 2022-2025 | Zurzuvae |
| Exeltis, USA INC. | $149.98 | 2019-2025 | Slynd |
| Mylan Pharmaceuticals INC. | $144.95 | 2019-2022 | |
| Therapeuticsmd, INC. | $118.34 | 2019-2022 | |
| Coopersurgical, INC. | $111.68 | 2019-2025 | Paragard T 380a |
| Sumitomo Pharma America, INC. | $104.37 | 2023-2025 | Myfembree, Gemtesa |
| Avion Pharmaceuticals | $101.17 | 2019-2023 | Balcoltra |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $100.52 | 2021-2024 | |
| Millicent US INC | $74.50 | 2024-2025 | Intrarosa, Femlyv |
| Hologic Sales and Service, LLC | $73.99 | 2023-2025 | Aptima, Thinprep 2000 Processor |
| Evofem Biosciences, INC. | $60.72 | 2022-2025 | Phexxi, Solosec, Phexx |
| Bayer Healthcare Pharmaceuticals INC. | $60.18 | 2019-2022 | |
| Meditrina | $49.96 | 2022-2023 | |
| Allergan, INC. | $37.46 | 2019-2020 | |
| Aspira Women'S Health INC | $28.82 | 2021 | |
| Medtronic, INC. | $18.99 | 2022 | |
| Duchesnay USA Incorporated | $18.50 | 2019 | |
| Scynexis, INC. | $13.36 | 2022 | |
| Vertical Pharmaceuticals, LLC | $12.01 | 2019 | |
| Mission Pharmacal Company | $11.29 | 2019 | |
| Organon LLC | $9.36 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kai Wu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.